SCHEMBL31695295

SCHEMBL31695295

COc1ccc(-c2cc(-c3ccc(F)cc3)[nH]c(=N)c2C#N)cc1O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48
▸ SQOR Q9Y6N5 5/20 0.42
▸ KMT2A Q03164 5/20 0.42
▸ MEN1 O00255 4/20 0.42
▸ USP2 O75604 2/20 0.42
▸ GSK3B P49841 1/20 0.41
▸ PIM1 P11309 2/20 0.41
▸ IL4 P05112 1/20 0.41
▸ TNKS O95271 1/20 0.40
▸ ALDH1A1 P00352 4/20 0.40
▸ MAPT P10636 4/20 0.40
▸ GAA P10253 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ NPSR1 Q6W5P4 2/20 0.40
▸ GLA P06280 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ MET P08581 1/20 0.39
▸ KDR P35968 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31695335 0.91 KDM4E (0.59) KDM4ETDP1SQORKMT2AMEN1
SCHEMBL29335410 0.90 KDM4E (0.49) KDM4ETDP1SQORKMT2AMEN1
SCHEMBL31695313 0.86 IL4 (0.54) KDM4ETDP1KMT2AMEN1GSK3B
SCHEMBL29335418 0.86 IL4 (0.54) KDM4ETDP1KMT2AMEN1GSK3B
SCHEMBL29331948 0.83 SQOR (0.53) KDM4ESQORKMT2AMEN1USP2
SCHEMBL31695360 0.81 IL4 (0.43) KDM4ETDP1KMT2AMEN1GSK3B
SCHEMBL31695334 0.81 IL4 (0.43) KDM4ETDP1KMT2AMEN1GSK3B
SCHEMBL29332196 0.78 TNKS (0.43) KDM4ETDP1KMT2AMEN1USP2
SCHEMBL23920029 0.78 PIM1 (0.47) KDM4ETDP1KMT2AMEN1PIM1
SCHEMBL31695352 0.78 ACMSD (0.49) KDM4ETDP1KMT2AMEN1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250313530-A1 SMALL MOLECULE INHIBITORS OF INTERLEUKIN-4 AND USES THEREOF TRUSTEES OF BOSTON UNIVERSITY (US) 2025-10-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250313530-A1 SMALL MOLECULE INHIBITORS OF INTERLEUKIN-4 AND USES THEREOF IL4, IRAK4, IL5 KDM4E 551/4885TDP1 4473/4885SQOR 3034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback